Published On: Tue, Oct 7th, 2014

Capstone Therapeutics Corp. (OTCMKTS:CAPS): Highlighted Growth Potential for AEM-28 Drug Class

Capstone Therapeutics Corp. (OTCMKTS:CAPS)’s Executive Chairman, John Holliman III, today published a blog post on TheChairmansBlog.com. He highlighted the larger growth potential for the company’s AEM-28 drug class. He also mentioned about the company’s collaborative research work with UAB and Lipimetix in exploring the full potential of this candidate. The development of AEM-28-02 analog will enhance the market size for AEM-28 drug class. AEM-28-02 is capable of catering to larger cardiovascular indications and enjoys longer patent life. Potential markets include Type 2 diabetes, acute coronary syndrome and peripheral artery disease estimated at more than $48 billion in combined annual market size.

Capstone Therapeutics Corp. (OTCMKTS:CAPS) is developing AEM-28 for a rare clinical indication called Homozygous Familial Hypercholesterolemia. AEM-28 could bypass a genetic defect responsible for this condition by shifting LDL uptake in these patients. AEM-28 has shorter patent life up to 2020. The drug is granted an orphan drug status by the U.S. FDA, allowing it seven years of market exclusivity. The drug was well-researched by the UAB scientists. Mr. Holliman also mentioned about Capstone’s joint venture with LipimetiX for new technology development. LipimetiX provides continuing support to the laboratory, which resulted in the discovery of new Apo E mimetic peptides. Even the analog AEM-28-02 has demonstrated more efficacious and more tolerable properties than AEM-28, in preclinical studies.

Capstone Therapeutics Corp. (OTCMKTS:CAPS) is developing a pipeline of clinically significant peptides for the therapies of cardiovascular disease. In 2012, the company ceases its internal operations, including clinical development of AZX100. In August 2014, the company returned all interest in and rights to AZX100 to the Licensor, AzTE. Currently, the company operates through virtual operating model. However, the company is committed to complying with the SEC rules and regulations and maintains the adequate level of corporate governance. Its corporate interests include management of AEM-28 development initiatives, under a licensing agreement with LipimetiX Development LLC.

© Copyright 2016 OTC News Magazine. All rights reserved.